This study is to determine whether or not the addition of liposomal bupivacaine in an ESP
block will have long term benefits for patients undergoing lumbar spinal fusion surgery.
Given previous studies found long term benefits from liposomal bupivacaine, the hypothesis is
that patients will have decreased opioid usage and improved pain scores when compared to a
standard ESP block with plain 0.25% bupivacaine.